Hepatitis B reactivation induced by Rituximab maintenance therapy for lymphoma.
Cho
Chun-Hung
CH
Hwang
Wen-Lee
WL
Cheng
Shao-Bin
SB
Lee
Teng-Yu
TY
Teng
Chieh-Lin
CL
D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects* / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D017074:Common Variable Immunodeficiency / Q000139:chemically induced / Q000150:complications; D005260:Female; D006509:Hepatitis B / Q000139:chemically induced* / Q000150:complications / Q000821:virology; D006515:Hepatitis B virus / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008223:Lymphoma / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D000069283:Rituximab; D014775:Virus Activation / Q000187:drug effects*
D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab